Navigation

Guangda Ma

Author Archive | Guangda Ma

External Evaluation of Vancomycin Models

January 10, 2021

Authors Guangda Ma (1), Eamon Duffy (1, 2), Jacqui Hannam (1), Nick Holford (1)
Affiliations (1) The University of Auckland, (2) Auckland District Health Board
Presentation type Poster
Presenters Guangda Ma

Attachments

Introduction Current clinical evidence supports area under the concentration-time curve (AUC) rather than trough concentrations as a more rational target for vancomycin therapy (1). In mid-2019 practice at Auckland District Health Board Hospitals transitioned from trough concentration to AUC guided dosing supported by Bayesian forecasting using the GAVamycin model implemented in NextDose (www.nextdose.org). To support […]

Continue Reading

The Influence of Genotype on Warfarin Dose Predictions

January 7, 2019

Authors Guangda Ma (1), Nick Holford (1), Jacqui Hannam (1), Jeff Harrison (1)
Affiliations 1. The University of Auckland
Presentation type Oral
Presenters Guangda Ma

Background & Aims: Warfarin is the most commonly prescribed oral anticoagulant worldwide, however, a narrow therapeutic range poses a barrier to safe and effective therapy. Common methods to predict warfarin dose requirements are biased at the extremes. When evaluated by simulation, Bayesian dose forecasting using a theory-based warfarin PKPD model achieves unbiased and precise dose predictions […]

Continue Reading

Performance of a Theory-Based Mechanistic Model for Predicting the Target Dose of Warfarin

January 24, 2018

Authors Guangda Ma (1), Nick Holford (1)
Affiliations 1. University of Auckland
Presentation type Oral
Presenters Guangda Ma

Background: Warfarin is widely used as a treatment of venous thromboembolism and its capability to reduce the hazard of thromboembolic events has been unequivocally demonstrated. Variability between individuals, as well as a narrow therapeutic range are barriers to safe and effective warfarin therapy. Inadequate dose individualization contributes to under-utilization, 18-55% of patients who would benefit […]

Continue Reading